|
|
|
|
|
Regulated Information
Information on the total number of voting rights and shares
Gosselies, Belgium, 29 May 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares on 28 April 2020 in a context of a private placement and on 7 May 2020 following the conversion of convertible bonds (CBs) issued in the private placement on 7 March 2018. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on regulated market.
Total amount of share capital on 25 March 2020 |
EUR 5,675,317 |
Total number of shares with voting rights on 25 March 2020 |
11,106,411 |
Total number of new shares issued on 28 April 2020 |
398,632 |
Total number of new shares issued on 7 May 2020 |
158,097 |
Total amount of share capital on 7 May 2020 |
EUR 5,959,249 |
Total number of shares with voting rights on 7 May 2020 |
11,663,140 |
Total number of voting rights (denominator) on 7 May 2020 |
11,663,140 |
Total number of attributed warrants |
69,331 |
Total number of convertible bonds outstanding |
1,722 (1) |
Total number of bond warrants and bond subscription rights outstanding |
2,235 (1) |
Total number of shares with voting rights that could be issued following the exercise of the attributed warrants, the bond warrants and bond subscription rights, and the conversion of the convertible bonds |
2,732,183 (2) |
(1) 105 CBs and 1,995 bond subscription rights were issued in the private placement of convertible bonds on 28 April 2020. Additionally, 1,600 CBs were issued in the private placements on 6 May 2020.
(2)
- 69,331 shares could be issued following the exercise of the 69,331 attributed warrants.
- 232,448 shares could be issued following the exercise and conversion of the 17 CBs and 240 bond warrants outstanding, issued in the private placements on 7 March 2018. The conversion is based on the conversion price of EUR 2.7640 (92% of the Volume-Weighted-Averaged-Price of Bone Therapeutics’ shares on 6 May 2020).
- 1,858,975 shares could be issued following the exercise and conversion of the 105 CBs and 1,995 bond subscription rights outstanding, issued in the private placements on 28 April 2020. The conversion is based on the conversion price of EUR 2.8241 (94% of the Volume-Weighted-Averaged-Price of Bone Therapeutics’ shares on 6 May 2020).
- 571,429 shares could be issued following the conversion of the 1,600 CBs outstanding, issued in the private placements on 6 May 2020. The conversion is based on the predetermined conversion price of EUR 7.00.
|
|
|
|
|
|
|
|
|
|
|
For further information, please contact:
Bone Therapeutics SA
Miguel Forte, MD, PhD, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Tel: +32 (0)71 12 10 00
investorrelations@bonetherapeutics.com
For International Media Enquiries
Image Box Communications
Neil Hunter / Michelle Boxall
Tel: +44 (0)20 8943 4685
neil@ibcomms.agency / michelle@ibcomms.agency
For French Media and Investor Enquiries
NewCap Investor Relations & Financial Communications
Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouillé
Tel: + 33 (0)1 44 71 94 94
bone@newcap.eu
|
|
|
|
|
|
|
|
|
Click here to unsubscribe
|
|
|
|
|
|
|
|
|